HC Wainwright Issues Optimistic Outlook for Affimed Earnings

Affimed (NASDAQ:AFMD) – Investment analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for shares of Affimed in a research report issued on Wednesday, December 18th. HC Wainwright analyst S. Ramakanth now anticipates that the biopharmaceutical company will post earnings of ($4.28) per share for the year, up from their prior forecast of ($4.31). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Affimed’s current full-year earnings is ($4.00) per share. HC Wainwright also issued estimates for Affimed’s Q4 2024 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.67) EPS and FY2025 earnings at ($3.02) EPS.

AFMD has been the topic of a number of other reports. Wells Fargo & Company cut their price objective on Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, December 12th. Stifel Nicolaus lowered their price objective on Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research note on Friday, November 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Affimed presently has an average rating of “Moderate Buy” and a consensus price target of $13.50.

Affimed Trading Up 4.2 %

Shares of Affimed stock opened at $1.24 on Monday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93. Affimed has a 12-month low of $1.14 and a 12-month high of $8.95. The company’s fifty day simple moving average is $2.84 and its two-hundred day simple moving average is $3.95.

Hedge Funds Weigh In On Affimed

Institutional investors and hedge funds have recently bought and sold shares of the stock. Choreo LLC bought a new stake in shares of Affimed during the 2nd quarter valued at $54,000. Point72 Asset Management L.P. lifted its position in Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 15,108 shares during the last quarter. Intellectus Partners LLC grew its position in Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 10,250 shares in the last quarter. Jane Street Group LLC bought a new stake in Affimed in the third quarter worth $44,000. Finally, FMR LLC grew its stake in shares of Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,086 shares during the last quarter. 30.82% of the stock is currently owned by hedge funds and other institutional investors.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.